DGAP-News: Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
(firmenpresse) - Synergy Pharmaceuticals
15.01.2013 11:00
---------------------------------------------------------------------------
NEW YORK, 2013-01-15 11:00 CET (GLOBE NEWSWIRE) --
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ('Synergy') today announced that it
convened its annual meeting of stockholders yesterday and it has received the
necessary approvals from its stockholders to authorize Synergy's merger with
Callisto Pharmaceuticals, Inc. ('Callisto') pursuant to the previously
announced Agreement and Plan of Merger, dated July 20, 2012, as amended on
October 15, 2012. Synergy and Callisto expect to close the merger as soon as
practicable.
In addition, the following other actions were approved by the stockholders at
the annual meeting:
-- an amendment to the Synergy's 2008 Equity Compensation Incentive Plan (the
'Plan') to increase the number of shares of Synergy common stock reserved
for issuance under the Plan from 7,500,000 to 15,000,000;
-- an amendment to the Synergy's Second Amended and Restated Certificate of
Incorporation to increase the number of authorized shares of Synergy common
stock from 100,000,000 to 200,000,000;
-- the seven (7) director nominees, all of whom currently serve as directors
of Synergy, were re-elected with a term to expire in 2013;
-- the appointment of BDO USA, LLP as Synergy's independent registered public
accounting firm for the fiscal year ended December 31, 2012 was ratified;
-- on an advisory basis, approved the compensation of Synergy's named
executive officers; and
-- on an advisory basis, selected a three (3) year frequency for an advisory
vote on executive compensation.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate plecanatide is a synthetic analog of the human gastrointestinal
hormone uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a Phase I study
of plecanatide in healthy volunteers, a Phase IIa clinical trial in CIC
patients, and has just completed a major Phase IIb/III clinical trial of
plecanatide to treat CIC. Plecanatide is also being developed to treat IBS-C,
with the first trial in IBS-C patients initiated in the fourth quarter of 2012.
Synergy's second GC-C agonist SP-333 is in clinical development to treat
inflammatory bowel diseases, and has just completed its first Phase I trial in
healthy volunteers. More information is available at
http://www.synergypharma.com.
CONTACT: Investor Contact:
Danielle Spangler
The Trout Group
synergy(at)troutgroup.com
(646) 378-2924
News Source: NASDAQ OMX
15.01.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Synergy PharmaceuticalsUnited States
Phone:
Fax:
E-mail:
Internet:
ISIN: US8716393082
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.01.2013 - 11:00 Uhr
Sprache: Deutsch
News-ID 219436
Anzahl Zeichen: 4068
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Synergy Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
